UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Leukemia, ISSN 0887-6924, 02/2014, Volume 28, Issue 2, pp. 289 - 292
AML | induction therapy | supportive care | high dose cytarabine | 3+7 | treatment-related mortality | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Induction Chemotherapy - adverse effects | Leukemia, Myeloid, Acute - mortality | Young Adult | Adolescent | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Aged | Retrospective Studies | Drug therapy | Usage | Patient outcomes | Index Medicus | treatment related mortality | time trend | age groups
Journal Article
Leukemia, ISSN 0887-6924, 01/2015, Volume 29, Issue 2, pp. 312 - 320
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Multivariate Analysis | Prognosis | Area Under Curve | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Treatment Outcome | Clinical Trials as Topic | Remission Induction | Neoplasm, Residual | Young Adult | Disease-Free Survival | Regression Analysis | Leukemia, Myeloid, Acute - diagnosis | Adolescent | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Mutation | Medical colleges | Medical research | Care and treatment | Analysis | Medicine, Experimental | Research | Health aspects | Blood cell count | Cancer | Genetic aspects | Drug resistance | Models | Oncology, Experimental | Myeloid leukemia | Leukemia | Health risks | Patients | White blood cells | Thermal resistance | Predictions | Cytogenetics | Remission | Pretreatment | Acute myeloid leukemia | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 986 - 996
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Confidence Intervals | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Remission Induction - methods | Odds Ratio | Daunorubicin - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Risk Assessment | Survival Rate | Treatment Outcome | Randomized Controlled Trials as Topic | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Leukemia, Myeloid, Acute - diagnosis | Infusions, Intravenous | Aminoglycosides - therapeutic use | Chemotherapy | Adults | Analysis | Cancer | Index Medicus
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 996 - 1000
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Costs | United States - epidemiology | Neoplasms - economics | Humans | Patient Participation | Patient Advocacy | Antineoplastic Agents - economics | Neoplasms - epidemiology | Prescription Fees | Neoplasms - drug therapy | Antimitotic agents | Cancer patients | Patient outcomes | Economic aspects | Dosage and administration | Drug therapy | Antineoplastic agents | Index Medicus | Abridged Index Medicus
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 2016, Volume 29, Issue 4, pp. 324 - 328
Hematology, Oncology and Palliative Medicine | AML | Phase 3 | Primary refractory AML | Acute myeloid leukemia | Relapsed AML | Life Sciences & Biomedicine | Hematology | Science & Technology | Clinical Trials, Phase III as Topic | Leukemia, Myeloid, Acute - diagnosis | Prognosis | Humans | Leukemia, Myeloid, Acute - therapy | Randomized Controlled Trials as Topic | Index Medicus
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 2014, Volume 27, Issue 3, pp. 235 - 240
Hematology, Oncology and Palliative Medicine | AML | cytarabine | HiDAC | MPFC | idarubicin | ara-C | allogeneic hematopoietic cell transplantation | daunorubicin | multiparameter flow cytometry | acute myeloid leukemia | day 14 | HCT | persistence | high-dose ara-C | Life Sciences & Biomedicine | Hematology | Science & Technology | Daunorubicin - therapeutic use | Cytarabine - therapeutic use | Humans | Hematopoietic Stem Cell Transplantation | Azacitidine - analogs & derivatives | Survival Rate | Cytarabine - analogs & derivatives | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Allografts | Time Factors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Transplantation Conditioning | Idarubicin - therapeutic use | Leukemia, Myeloid, Acute - therapy | Azacitidine - therapeutic use | Chemotherapy | Anthracyclines | Cancer | Index Medicus
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 2009, Volume 22, Issue 4, pp. 529 - 536
Hematology, Oncology and Palliative Medicine | CRp | reduced-intensity transplant | older | treatment-induced death | acute myeloid leukaemia | resistance | Life Sciences & Biomedicine | Hematology | Science & Technology | Leukemia, Myeloid, Acute - diagnosis | Prognosis | Humans | Middle Aged | Aged, 80 and over | Aged | Cytogenetic Analysis | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Aged patients | Transplantation | Hematopoietic stem cells | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 64 - 64
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 2013, Volume 26, Issue 3, pp. 261 - 268
Hematology, Oncology and Palliative Medicine | AML | CD30 | antibody | antigen | brentuximab | 225Actinium | immunoconjugates | acute promyelocytic leukemia | gentuzumab ozogamicin | acute myeloid leukemia | APL | CD45 | CD33 | SGN-CD331 | Life Sciences & Biomedicine | Hematology | Science & Technology | Antigens, CD - immunology | Gene Expression | Antibodies, Monoclonal, Humanized - therapeutic use | Prognosis | Standard of Care | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Acute - immunology | Antigens, CD - genetics | Transplantation, Homologous | Randomized Controlled Trials as Topic | Leukemia, Myeloid, Acute - mortality | Leukemia, Myeloid, Acute - diagnosis | Survival Analysis | Immunoconjugates - therapeutic use | Aged | Leukemia, Myeloid, Acute - therapy | Aminoglycosides - therapeutic use | Chemotherapy | Cancer | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 2686 - 2686
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 129 - 129
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 540 - 540
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 2011, Volume 24, Issue 4, pp. 515 - 522
Hematology, Oncology and Palliative Medicine | older | induction | acute myeloid leukemia | age | Life Sciences & Biomedicine | Hematology | Science & Technology | United States - epidemiology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Cytarabine - therapeutic use | Humans | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Anthracyclines - administration & dosage | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Remission Induction - methods | Risk Assessment | Leukemia, Myeloid, Acute - pathology | Treatment Outcome | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Biomarkers, Tumor - genetics | Disease Management | Anthracyclines - therapeutic use | Karyotype | Leukemia, Myeloid, Acute - genetics | Anthracyclines | Oncology, Experimental | Analysis | Cytogenetics | Aged patients | Research | Cancer | Index Medicus
Journal Article
The Lancet. Haematology, ISSN 2352-3026, 2016, Volume 3, Issue 7, pp. e330 - e339
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Hematology | Science & Technology | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Male | Cytarabine - administration & dosage | Cord Blood Stem Cell Transplantation | Young Adult | Arabinonucleosides - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Infusions, Intravenous | Adenine Nucleotides - administration & dosage | Neoplasm Staging | Leukemia, Myeloid, Acute - physiopathology | Leukemia, Myeloid, Acute - therapy | Cohort Studies | Granulocyte Colony-Stimulating Factor - administration & dosage | Index Medicus
Journal Article
American journal of hematology, ISSN 0361-8609, 08/2016, Volume 91, Issue 8, pp. 824 - 846
Journal Article